MAIA Biotechnology, Inc. (MAIA)
Automate Your Wheel Strategy on MAIA
With Tiblio's Option Bot, you can configure your own wheel strategy including MAIA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MAIA
- Rev/Share 0.0
- Book/Share 0.1279
- PB 9.3793
- Debt/Equity 0.0
- CurrentRatio 2.1894
- ROIC -3.2963
- MktCap 44438768.0
- FreeCF/Share -0.5205
- PFCF -2.8178
- PE -2.2484
- Debt/Assets 0.0
- DivYield 0
- ROE -4.5968
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors
Published: December 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company's Board of Directors purchased approximately 182,445 shares of MAIA common stock at market price between November 21 and 28, 2025. The average common stock price was $1.06.
Read More
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
Published: November 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries
Read More
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: October 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey
Read More
MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer
Published: September 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC)
Read More
MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a manuscript detailing developments in its Phase 2 THIO-101 clinical trial was accepted and published in the international peer-reviewed open access scientific journal, Cells, in a special issue, “Cellular Mechanisms of Anti-Cancer Therapies”
Read More
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
New York, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA) following quarterly results. The update note includes detailed information on the MAIA Biotechnology's business, recent updates, management commentary, financial results, valuation, and risks.
Read More
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy.
Read More
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
Published: July 09, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer.
Read More
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
Published: June 18, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies.
Read More
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial.
Read More
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer.
Read More
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Published: May 15, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.
Read More
Best Momentum Stocks to Buy for May 6th
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
MAIA, BYRN and OCX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 6, 2025.
Read More
New Strong Buy Stocks for May 6th
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
MAIA, BYRN, OCX, BBVA and HMY have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2025.
Read More
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
Published: May 05, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement.
Read More
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
MAIA Biotechnology, Inc. (MAIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025.
Read More
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
Published: February 24, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million.
Read More
MAIA Biotechnology Announces Private Placement of $2,715,000
Published: February 18, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of $2,715,000.
Read More
About MAIA Biotechnology, Inc. (MAIA)
- IPO Date 2022-07-28
- Website https://www.MAIABiotech.com
- Industry Biotechnology
- CEO Vlad Vitoc
- Employees 13